Polyomavirus-associated nephropathy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Dec 24, 2012; 2(6): 84-94
Published online Dec 24, 2012. doi: 10.5500/wjt.v2.i6.84

Table 3 Algorythm for the virological monitoring of polyomavirus BK replication in renal transplantation[49]

Assay	Notes	Timing - intervention
Screening	Positive screening test (possible PVAN)	Every 3 mo up to 2 yr post-transplantation or in case of allograft dysfunction or when renal biopsy is performed
Urine cytology (decoy cells) or urine DNA load	Positive screening test (possible PVAN)
Adjunctive quantitative tests (threshold)	Presumptive PVAN	Pre-emptive reduction of immunosuppression
Urine DNA load > 10⁷ copies/mL or plasma DNA load > 10⁴ copies/mL		Pre-emptive reduction of immunosuppression
Allograft biopsy	Definitive diagnosis of PVAN
Monitoring of response to treatment		Every 2-4 wk
Urine DNA load decreasing or plasma DNA load decreasing		Every 2-4 wk
Serum creatinine
	Negative monitoring test (resolved PVAN)

PVAN: Polyomavirus-associated nephropathy.

Citation: Costa C, Cavallo R. Polyomavirus-associated nephropathy. World J Transplant 2012; 2(6): 84-94
URL: https://www.wjgnet.com/2220-3230/full/v2/i6/84.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i6.84

Costa C, Cavallo R. Polyomavirus-associated nephropathy. World J Transplant 2012; 2(6): 84-94 [PMID: 24175200 DOI: 10.5500/wjt.v2.i6.84]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.